article thumbnail

Public Health Product Hops

Bill of Health

Yet Dmitry Karshtedt held otherwise at the ASLME Health Law Professor’s Conference in Atlanta, GA in 2017. In each scenario, public health considerations drove the product switches and the FDA actively encouraged the development of reformulated products. My talk was titled “Legal Approaches to Ensuring Timely Generic Drug Availability.”

article thumbnail

FDA, MITRE Update Medical Device Cybersecurity Regional Incident Preparedness and Response Playbook

HIPAA Journal

Following the WannaCry ransomware attacks in 2017, which caused massive disruption to clinical operations at several U.S. The post FDA, MITRE Update Medical Device Cybersecurity Regional Incident Preparedness and Response Playbook appeared first on HIPAA Journal.

FDA 87
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Five Reasons why the FDA got it Right with Digital Health

The Digital Health Corner

The FDA recently announced its Digital Health Innovation Action Plan. Digital health differs significantly from drugs and traditional medical devices around which the FDA has developed its structure and policies over decades. The FDA will have new digital health experts. This plan was both important and necessary.

FDA 87
article thumbnail

Cognoa Appoints Former CMO, Dr. Sharief Taraman as CEO

HIT Consultant

– Dr. Taraman served as the company’s Chief Medical Officer since 2017, leading clinical evidence generation and regulatory milestones of Canvas Dx and those resulting in FDA Breakthrough Device Designation of Cognoa’s autism digital therapeutic.

FDA 95
article thumbnail

FDA Guidance Shows a Regulatory Path Forward for Interoperable Devices

Exeed Regulatory Compliance

A new FDA guidance offers helpful recommendations for design and premarket submission. According to a 2018 Deloitte Consulting report, the market for interconnected medical devices is expected to grow from $15 billion in 2017 to $52 billion by 2025. Medical device industry is changing fast!

FDA 52
article thumbnail

False and Deceptive Health Claims: Buyers Beware

Bill of Health

The FDA’s primary responsibility is over claims that appear on product labels (including packaging, product inserts, and promotional material at the point of sale), and the FTC regulates claims made in advertising in general. FDA regulations prescribe different standards for different products and claims. million to consumers.

FDA 184
article thumbnail

FDA Unlocks the Key to Innovation in Interoperable Medical Devices

Exeed Regulatory Compliance

According to a 2018 report from Deloitte , the IoMT market is expected to grow from $41 billion in 2017 to $158 billion by 2022. Regulatory Breakthrough In a small step towards achieving the vision of interoperable medical devices, the FDA has recently authorized marketing of a novel software medical device using the De Novo Classification.

FDA 52